| Literature DB >> 35164229 |
Hafiz Abdul Khaliq1,2,3, Sergio Ortiz1, Mireille Alhouayek2, Giulio G Muccioli2, Joëlle Quetin-Leclercq1.
Abstract
Convolvulus arvensis is used in Pakistani traditional medicine to treat inflammation-related disorders. Its anti-inflammatory potential was evaluated on hexane, dichloromethane, ethyl acetate, methanol, and aqueous extracts of whole plant on pro-inflammatory mediators in LPS-activated murine macrophage J774 cells at the non-cytotoxic concentration of 50 µg/mL. Ethyl acetate (ARE) and methanol (ARM) extracts significantly decreased mRNA levels of IL-6, TNF-α, MCP-1, COX-2, and iNOS. Furthermore, both extracts dose dependently decreased IL-6, TNF-α, and MCP-1 secretion. Forty-five compounds were putatively identified in ARE and ARM by dereplication (using HPLC-UV-HRMSn analysis and molecular networking), most of them are reported for the first time in C. arvensis, as for example, nineteen phenolic derivatives. Rutin, kaempferol-3-O-rutinoside, chlorogenic acid, 3,5-di-O-caffeoylquinic acid, N-trans-p-coumaroyl-tyramine, and N-trans-feruloyl-tyramine were main constituents identified and quantified by HPLC-PDA in ARE and ARM. Furthermore, chlorogenic acid, tyramine derivatives, and the mixture of the six identified major compounds significantly decreased IL-6 secretion by LPS-activated J774 cells. The activity of N-trans-p-coumaroyl-tyramine is shown here for the first time. Our results indicate that ARE, ARM and major constituents significantly inhibited the expression of pro-inflammatory mediators, which supports the use of this plant to treat inflammatory diseases.Entities:
Keywords: GNPS; HPLC-UV-HRMS; biological screening; field bindweed; inflammation; molecular networking; phenolics
Mesh:
Substances:
Year: 2022 PMID: 35164229 PMCID: PMC8838012 DOI: 10.3390/molecules27030963
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Effect of the crude extracts on cell viability. WI38 and J774 cells were treated with 50 and 100 µg/mL of the crude extracts or vehicle (DMSO and EtOH-H2O (25:75)) for 72 h. Then, an MTT assay was performed. Data are expressed as mean ± SEM. n = 2 in triplicates.
Figure 2Effect of ARE and ARM on the expression of pro-inflammatory mediators in LPS-stimulated J744 cells. (A–E) Cells were incubated with crude extracts (50 µg/mL), or vehicle (Veh., 0.25% DMSO) and LPS (100 ng/mL) for 8 h. mRNA levels of IL-6, TNF-α, MCP-1, COX-2, and iNOS were analyzed by RT-qPCR with RPL19 used as reference gene. Results are expressed in percentage of the LPS-vehicle condition. (F–H) Cells were incubated with crude extracts, or vehicle (Veh., 0.25% DMSO) and LPS (100 ng/mL) for 8 h. IL-6, TNF-α, and MCP-1 protein levels in the supernatant medium were quantified by ELISA. IL-6, TNF-α, and MCP-1 were not detected in the medium of the unstimulated, vehicle-treated cells. The data were analyzed by the one-way ANOVA followed by Dunnet’s post hoc test for comparisons between groups, are expressed as mean ± SEM. n = 3 in triplicates, *** p < 0.001, **** p < 0.0001 vs. Veh.
Putative identification of chemical constituents present in C. arvensis extracts (ARE and ARM) by comparison of the MS2 data (Negative mode, APCI).
| Code | tR [min] | λmax | MS Major Ion(s) | MS/MS Fragments [ | Molecular Formula | Δ ppm | Δ mDa | Putative Identification | Isolated Previously a | Ref. | |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| 3.20 | n.d. | 387.1147 | [M + HCOO−]− | 179.0563 b | C12H22O11 | 0.04 | 0.01 | Sucrose | ||
| 341.1084 | [M − H]− | ||||||||||
| 729.2287 | [2M + HCOO−]− | ||||||||||
| 683.2222 | [2M − H]− | ||||||||||
|
| 3.28 | n.d. | 151.0613 | [M − H]− | 71.0142; 101.0247; 133.0509 b | C5H12O5 | 4.31 | 0.65 | Xylitol # | ||
| 197.0664 | [M + HCOO−]− | ||||||||||
|
| 3.40 | n.d. | 181.0722 | [M + HCOO−]− | 135.0669 c | C5H12O4 | −2.01 | −0.27 | 2-methyl-1,2,3,4-butanetetrol # | ||
| 135.0668 | [M − H]− | ||||||||||
|
| 3.39 | 270 | 191.0567 | [M − H]− | 85.0299; 127.0405; 173.0458; 93.0350 b | C7H12O6 | 5.95 | 1.14 | Quinic acid # |
| [ |
| 383.1199 | [2M − H]− | ||||||||||
|
| 3.59 | n.d. | 239.0775 | [M + HCOO−]− | 133.0509; 59.0141 b | C7H14O6 | 5.93 | 1.09 | |||
| 193.0723 | [M − H]− | ||||||||||
|
| 3.96 | n.d. | 239.0772 | [M + HCOO]− | 193.0718; 133.0508; 59.0141 b | C7H14O6 | 2.12 | 0.51 | |||
|
| 4.90 | n.d. | 239.0772 | [M + HCOO−]− | 133.0508; 59.0141 b | C7H14O6 | 3.04 | 0.59 | |||
| 193.0718 | [M − H]− | ||||||||||
| 712.5355 | [M − H]− | ||||||||||
|
| 4.98 | n.d. | 117.0198 | [M − H]− | 73.0297; 99.0091 b | C4H6O4 | 8.69 | 1.02 | Succinic acid # | ||
|
| 5.06 | n.d. | 281.0881 | [M − H]− | 235.0820; 263.0955 b | C10H18O9 | 3.00 | 0.84 | Xylobiose # | ||
|
| 5.68 | n.d. | 341.0889 | [M − H]− | 179.0348; 167.0349; 135.0451 b | C15H18O9 | 4.82 | 1.64 | |||
|
| 6.02 | n.d. | 451.2199 | [M + HCOO−]− | 167.1076; 179.0560; 243.1596 b | C19H34O9 | −3.60 | −1.46 | Magastigmane glycoside derivative I # | ||
| 405.2110 | [M − H]− | ||||||||||
|
| 6.18 | 289; 325 | 433.2091 | [M + HCOO−]− | 387.2012; 179.0559; 161.0454 c | C19H32O8 | 3.99 | 1.73 | Magastigmane glycoside derivative II # | ||
|
| 6.21 | n.d. | 353.0881 | [M − H]− | 191.0559; 179.0350; 173.0455; 135.0452 b | C16H18O9 | 2.39 | 0.84 | Chlorogenic acid * |
| [ |
|
| 7.30 | 315 | 369.0820 | [M + HCOO−]− | 323.0769; 161.0243 b | C15H16O8 | 0.64 | 0.21 | Skimmin # |
| [ |
| 323.0769 | [M − H]− | ||||||||||
|
| 7.97 | n.d. | 395.1930 | [M + HCOO−]− | 187.1341; 161.0457; 179.0563 b | C16H30O8 | 5.03 | 1.76 | Monoterpenoid glycoside I # | ||
| 349.1880 | [M − H]− | ||||||||||
|
| 8.66 | 245; 324 | 353.0881 | [M − H]− | 191.0560; 179.0350 b | C16H18O9 | 2.39 | 0.84 |
| [ | |
| 707.1868 | [2M − H]− | ||||||||||
|
| 9.06 | 288 | 433.2091 | [M + HCOO−]− | 161.0455 b | C19H32O8 | −2.88 | −1.12 | Magastigmane glycoside derivative III # | ||
| 387.2014 | [M − H]− | ||||||||||
|
| 10.20 | 287 | 387.1870 | [M − H]− | 207.1022; 163.1128; 369.1544 b | C15H32O11 | 0.94 | 0.36 | n.i. | ||
|
| 10.51 | n.d. | 431.1928 | [M + HCOO−]− | 223.1337; 205.1233; 153.0922; 161.0457 b | C19H30O8 | 1.97 | 0.76 | Roseoside # |
| [ |
| 385.1853 | [M − H]− | ||||||||||
|
| 11.36 | 322 | 297.0986 | [M − H]− | 179.0352; 135.0453 b | C14H18O7 | 3.95 | 1.17 | n.i. | ||
|
| 12.13 | 265 | 441.1969 | [M + HCOO−]− | n.s. | C17H32O10 | −4.61 | −1.82 | n.i. | ||
| 395.1899 | [M − H]− | ||||||||||
|
| 12.28 | n.d. | 281.1397 | [M − H]− | 237.1488; 171.1180; 123.0817; 201.1284 b | C15H22O5 | 2.85 | 0.80 | n.i. | ||
|
| 12.97 | 258 | 583.2027 | [M + HCOO−]− | n.s. | C26H34O12 | −1.49 | −0.80 | n.i. | ||
| 537.1964 | [M − H]− | ||||||||||
| 1187.3107 | [2M − H]− | ||||||||||
| 1613.8181 | [M − H]− | ||||||||||
|
| 13.26 | 242; 298; 324 | 179.0353 | [M − H]− | 135.0453 b | C9H8O4 | 4.84 | 0.87 | Caffeic acid # |
| [ |
|
| 14.25 | 255; 331 | 741.1902 | [M − H]− | 300.0269; 609.1447; 301.0347; 591.1343; 271.0242 b | C32H38O20 | 3.21 | 2.38 | Quercetin- | ||
|
| 14.33 | 294; 326 | 367.1024 | [M − H]− | 191.0559; 173.0455; 193.0499 b | C17H20O9 | −1.38 | −0.51 | Feruloyl quinic acid # | ||
|
| 14.78 | n.d. | 225.1138 | [M − H]− | 181.1234; 165.0921; 147.0816; 135.0816 b | C12H18O4 | 4.96 | 1.12 | Tuberonic acid # |
| [ |
|
| 16.09 | n.d. | 725.1935 | [M − H]− | 593.1494; 575.1391; 284.0317; 285.0394; 327.0500 b | C32H38O19 | 0.82 | 0.60 | Kaempferol- | ||
|
| 16.54 | 254; 347 | 609.1460 | [M − H]− | 301.0349; 300.0276; 271.0248; 343.0454 b | C27H30O16 | 0.72 | 0.44 | Rutin * |
| [ |
| 1219.3008 | [2M − H]− | ||||||||||
|
| 16.78 | n.d. | 621.3154 | [M + HCOO−]− | 557.2985 b | C28H48O12 | 3.91 | 2.25 | n.i. | ||
| 575.3090 | [M − H]− | ||||||||||
|
| 17.24 | n.d. | 665.3405 | [M + HCOO−]− | 619.3352; 601.3245 c | C31H54O15 | 3.61 | 2.23 | n.i. | ||
|
| 17.84 | n.d. | 709.3664 | [M + HCOO−]− | 645.3510; 663.3615 c | C32H56O14 | 2.45 | 1.74 | n.i. | ||
|
| 18.00 | 240; 301; 325 | 593.1503 | [M − H]− | 285.0398; 284.0325; 327.0507; 255.0297 b | C27H30O15 | −0.58 | −0.35 | Kaempferol- | ||
|
| 18.36 | 309 | 753.3912 | [M + HCOO−]− | 689.3768; 707.3875 c | C34H60O15 | 0.43 | 0.32 | n.i. | ||
|
| 18.73 | 238; 265; 342 | 593.1503 | [M − H]− | 285.0369; 327.0500 b | C27H30O15 | −0.58 | −0.35 | Kaempferol-3- |
| [ |
| 1187.3107 | [2M − H]− | ||||||||||
|
| 19.20 | 297; 342 | 607.1292 | [M − H]− | 463.0877; 505.0982; 545.1293; 301.0352 b | C27H28O16 | −1.17 | −0.71 | Quercetin- | ||
|
| 19.56 | 301; 325 | 447.0950 | [M − H]− | 284.0324; 285.0399; 327.0507; 255.0297 b | C21H20O11 | 5.06 | 2.26 | Kaempferol-3- |
| [ |
|
| 19.69 | 238; 325 | 515.1215 | [M − H]− | 353.0858; 173.0454; 335.0765; 179.0347 b | C25H24O12 | 4.95 | 2.55 | 3,4-di- |
| [ |
| 1031.2482 | [2M − H]− | ||||||||||
|
| 20.06 | n.d. | 511.2174 | [M + HCOO−]− | 161.0245; 179.0350 c | C24H34O9 | −1.05 | −0.54 | n.i. | ||
| 929.4974 | [2M − H]− | ||||||||||
|
| 20.52 | n.d. | 973.5257 | [M − H]− | 909.508 b | C46H78N4O18 | 2.48 | 2.41 | n.i. | ||
|
| 20.96 | 245; 295; 327 | 515.1211 | [M − H]− | 353.0868; 191.056; 179.0349 b | C25H24O12 | 4.17 | 2.15 | 3,5-di- |
| [ |
| 561.1236 | [M + HCOO−]− | ||||||||||
| 1031.2471 | [2M − H]− | ||||||||||
|
| 21.67 | n.d. | 417.0831 | [M − H]− | 284.0323; 285.0397; 327.0506; 255.0295 b | C20H18O10 | 2.23 | 1.80 | Kaempferol- | ||
|
| 21.86 | 245; 293; 324 | 515.1214 | [M − H]− | 353.0866; 299.056; 173.0457; 203.0350; | C25H24O12 | 2.37 | 0.93 | 4,5-di- | ||
| 1031.2463 | [2M − H]− | ||||||||||
|
| 22.49 | n.d. | 187.0981 | [M − H]− | 125.0975; 97.0663 b | C9H16O4 | 5.70 | 1.07 | Azelaic acid # | ||
|
| 22.93 | n.d. | 625.2126 | [M + HCOO−]− | n.s. | C28H36O13 | −0.98 | −0.57 | n.i. | ||
| 579.2072 | [M − H]− | ||||||||||
|
| 24.91 | n.d. | 529.1365 | [M − H]− | 353.0868; 367.1023; 191.0561 b | C26H26O12 | 3.59 | 1.90 | Caffeoyl-feruloyl quinic acid isomer I # | ||
|
| 25.41 | n.d. | 529.1372 | [M − H]− | 367.1016; 173.0454; 193.0506; 179.0349 b | C26H26O12 | 4.91 | 2.60 | Caffeoyl-feruloyl quinic acid isomer II # | ||
|
| 26.09 | 292; 305 | 282.1146 | [M − H]− | 119.0506; 145.0296; 162.0563 b | C17H17NO3 | 5.61 | 1.58 |
| [ | |
| 328.1194 | [M + HCOO−]− | ||||||||||
|
| 26.67 | 238; 293; 318 | 312.1243 | [M − H]− | 178.0512; 297.1007; 135.0454 b | C18H19NO4 | 2.30 | 0.72 |
| [ | |
| 358.1294 | [M + HCOO−]− | ||||||||||
|
| 28.04 | n.d. | 607.2026 | [M + HCOO−]− | 561.1960 c | C28H34O12 | −0.13 | −0.08 | n.i. | ||
|
| 29.36 | n.d. | 327.2182 | [M − H]− | 229.1438; 291.1964, 211.1336; 171.1029 b | C18H32O5 | 3.21 | 1.05 | Trihydroxy-10,15-octadecadienoic acid derivative I # | ||
|
| 30.56 | n.d. | 327.2178 | [M − H]− | 229.1437; 291.1961; 171.1027; 211.1336; 309.2067 b | C18H32O5 | 1.99 | 0.65 | Trihydroxy-10,15-octadecadienoic acid derivative II # | ||
|
| 31.36 | n.d. | 329.2329 | [M − H]− | 329.2333; 229.1440; 211.1337; 171.1030; 311.2228; 293.2122 b | C18H34O5 | 0.31 | 0.10 | Trihydroxy-10-octadecenoic acid # | ||
|
| 31.90 | n.d. | 883.4227 | [M + HCOO−]− | 561.6332; 533.2184 b | C39H66O19 | 2.62 | 2.20 | |||
| 837.4142 | [M − H]− | ||||||||||
|
| 32.54 | n.d. | 721.3635 | [M + HCOO−]− | 397.1340 b | C33H56O14 | −0.86 | −0.58 | |||
| 675.3586 | [M − H]− | ||||||||||
| 712.5355 | [M − H]− | ||||||||||
|
| 33.05 | n.d. | 647.3270 | [M + HCOO−]− | n.s. | C30H50O12 | −1.67 | −1.00 | n.i. | ||
| 601.3214 | [M − H]− | ||||||||||
|
| 33.53 | 218 | 559.3091 | [M + HCOO−]− | 277.2170; 253.0926 c | C27H46O9 | −4.89 | −2.74 | |||
|
| 34.56 | 215 | 699.3825 | [M + HCOO]− | 397.1340 c | C31H58O14 | 3.13 | 2.19 | |||
|
| 35.20 | n.d. | 1659.8471 | [M + HCOO−]− | n.s. | C98H118O20 | 2.65 | 4.28 | n.i. | ||
| 1613.8181 | [M − H]− | ||||||||||
|
| 35.87 | 218 | 819.5250 | [M + HCOO−]− | 773.5198; 277.2170; 513.3065 b | C45H74O10 | −0.74 | −0.57 | |||
| 773.5198 | [M − H]− | ||||||||||
|
| 38.25 | 409 | 997.5783 | [M + HCOO−]− | n.s. | C51H84O16 | 4.40 | 4.19 | n.i. | ||
| 951.5723 | [M − H]− | ||||||||||
|
| 38.70 | 218 | 765.5196 | [M − H]− | 505.3003; 255.2320; 277.2163; 527.2846; 747.5024 b | C43H74O11 | 5.63 | 4.31 | n.i. | ||
|
| 40.11 | 409 | 591.2607 | [M − H]− | 559.2329; 515.2441 b | C34H40O9 | 2.19 | 1.29 | n.i. | ||
|
| 40.69 | n.d. | 1835.8597 | [M − H]− | n.s. | C116H124O20 | −0.58 | −1.07 | n.i. | ||
|
| 41.44 | n.d. | 758.5413 | [M + HCOO−]− | n.s. | C41H71N5O5 | −3.08 | −2.20 | n.i. | ||
| 712.5355 | [M − H]− |
a Previously isolated from Convolvulaceae family species; b fragments produced from [M − H]− adduct; c fragments produced from [M + HCOO−]− adduct; n.d., not detectable by overlapping with near chromatographic compounds; n.s., no significant signals; n.i., no identified compound; * compounds identified by standard comparison. # compounds identified in C. arvensis for the first time.
Figure 3Molecular network of A: flavonoid glycosides; B: phenolic acids; C: lipid acids, D: flavonoid triglycosides; E: lipid glycosides. Clusters were built with a cosine of 0.7 with a minimum of 4 matched peaks. Size of nodes are proportional to corresponding peak area. Edge width are proportional to the corresponding cosine value. Compounds marked with * were additionally identified by standard comparison.
Figure 4UV chromatogram of ARE and ARM at 254 nm. Chlorogenic acid (13), rutin (29), kaempferol-3-O-rutinoside (35), 3,4-di-O-caffeoylquinic acid (38), 3,5-di-O-caffeoylquinic acid (41), 4,5-di-O-caffeoylquinic acid (43), N-trans-p-coumaroyltyramine (48), and N-trans-feruloyltyramine (49).
Major phenolic compounds quantified in ARE and ARM.
| ID | Compound | Regression Equation | R2 | LOD | LOQ | ARE | ARM | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Conc. in Crude Extract | Concentration in 50 µg of Extract/mL | Conc. in Crude Extract | Concentration in 50 µg of Extract/mL | ||||||||
| (µg/mL) | (µM) | (µg/mL) | (µM) | ||||||||
|
| Chlorogenic acid | y = 40320x + 99146 | 0.9996 | 4.37 | 13.24 | 1.51 ± 0.04 | 0.08 ± 0.00 | 0.21 ± 0.01 | 29.86 ± 0.17 | 1.49 ± 0.01 | 4.22 ± 0.02 |
|
| Rutin | y = 26787x + 147669 | 0.9997 | 5.11 | 15.48 | 0.78 ± 0.19 | 0.04 ± 0.01 | 0.06 ± 0.02 | 27.71 ± 0.19 | 1.39 ± 0.01 | 2.27 ± 0.02 |
|
| Kaempferol-3- | y = 36219x + 52756 | 0.9996 | 4.16 | 12.60 | 2.18 ± 0.02 | 0.11 ± 0.00 | 0.18 ± 0.00 | 5.23 ± 0.19 | 0.26 ± 0.01 | 0.44 ± 0.02 |
|
| 3,5-di- | y = 59073x + 308772 | 0.9971 | 8.68 | 26.32 | 5.82 ± 0.32 | 0.29 ± 0.02 | 0.56 ± 0.03 | 38.16 ± 0.13 | 1.91 ± 0.01 | 3.70 ± 0.01 |
|
| y = 88859x + 21246 | 0.9997 | 1.81 | 5.47 | 5.90 ± 0.27 | 0.30 ± 0.01 | 1.04 ± 0.05 | 1.72 ± 0.13 | 0.09 ± 0.01 | 0.30 ± 0.02 | |
Relative content of major phenolic compounds of ARE and ARM, expressed as: a mg of 3,5-di-O-caffeoylquinic acid equivalent; b mg of N-trans-p-coumaroyltyramine equivalent.
| ID | Compound | ARE | ARM | ||||
|---|---|---|---|---|---|---|---|
| Conc. in Crude Extract | Concentration in 50 µg of Extract/mL | Conc. in Crude Extract | Concentration in 50 µg of Extract/mL | ||||
| (µg/mL) | (µM) | (µg/mL) | (µM) | ||||
|
| 3,4-di- | 1.48 ± 0.04 a | 0.07 ± 0.00 a | 0.14 ± 0.00 a | 14.08 ± 0.81a | 0.704 ± 0.04 a | 1.36 ± 0.08 a |
|
| 4,5-di- | 1.97 ± 0.03 a | 0.10 ± 0.00 a | 0.19 ± 0.00 a | 21.34 ± 0.06 a | 1.067 ± 0.00 a | 2.07 ± 0.01 a |
|
| 6.61 ± 0.40 b | 0.33 ± 0.02 b | 1.06 ± 0.06 b | 1.37 ± 0.30 b | 0.068 ± 0.02 b | 0.22 ± 0.05 b | |
Figure 5Effect of ARE, ARM, standards, and the mixture of standards on the expression of IL-6 in LPS-stimulated J744 cells. Cells were incubated with standards (5 µM), their mixture (same concentration of standards as in 50 µg/mL ARM), or vehicle (Veh., 0.25% DMSO) and LPS (100 ng/mL) for 8 h. IL-6 protein levels in the supernatant medium were quantified by ELISA. IL-6 was not detected in the medium of the unstimulated, vehicle-treated, cells. Results are expressed as percentage of the LPS-vehicle condition. The data were analyzed by the one-way ANOVA followed by Dunnet’s post hoc test for comparisons between groups, are expressed as mean ± SEM. n = 4 in triplicates, ** p < 0.05, **** p < 0.0001 vs. Veh. Rutin (29); kaempferol-3-O-rutinoside (35); chlorogenic acid (3-O-caffeoylquinic acid) (13); 3,5-di-O-caffeoylquinic acid (41); N-trans-p-coumaroyltyramine (48); N-trans-feruloyltyramine (49); mixture (29, 35, 13, 41, 48, 49).
Primer sequences for qPCR.
| Gene/Product | Forward Primer (5′ to 3′) | Reverse Primer (5′ to 3′) |
|---|---|---|
| ACAAGTCGGAGGCTTAATTACACAT | TTGCCATTGCACAACTCTTTTC | |
| CTACTGAACTTCGGGGTGATC | TGAGTGTGAGGGTCTGGGC | |
| GTCCCAAAGAAGCTGTAGTTTTTG | ATGTATGTCTGGACCCATTCC | |
| TGACCTGGATGAGAAGGATGAG | CTGTGATACATATGGCGGTCAATC | |
| TGACCCCCAAGGCTCAAATAT | TGAACCCAGGTCCTCGCTTA | |
| AGGTACTCAGCGTGCTCCAC | GCACCGAAGATATCTTCATG |